Skip to main content
Premium Trial:

Request an Annual Quote

Genizon Raises $10.6M in VC Debt Financing; Partner Illumina Ponies Up $3M

NEW YORK, March 29 (GenomeWeb News) - Genizon has raised CA$12.4 million ($10.6 million) in a first tranche of a secured convertible debenture financing, the company said today.


The company will use the cash to "substantially add to its inventory of GeneMaps and drug targets directly implicated in common diseases," John Hooper, president and CEO of Genizon, said in a statement.


Investors in the round include HBM Bioventures, Biofund Management, MVI Finance and Carnegie, as well as Genizon management, directors and employees, private investors, and partner Illumina, which ponieed up CA$3.5 million and certain warrants, according to an SEC filing today.


As GenomeWeb News reported earlier this year, Genizon will use Illumina's whole-genome genotyping platform for its disease-association research program.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.